November 1, 2007Frontiers in bioscienceOpen Access

Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, "decoy peptide"

View Full Paper

Ask AI

Bookmark

Population

In vitro models and animal models of diabetes nephropathy and retinopathy

Design

Review

Authors

MUMukarram UddinSUNY College of Environmental Science and Forestry

Discussion

Member takes

Implication

May support prorenin-targeted therapies for diabetic complications; leaves open translation from animal data to human trials.

Structured PICO

Population

In vitro models and animal models of diabetes nephropathy and retinopathy

Intervention

Prorenin prosegment "decoy peptide" (decapeptides 10P-19P) and "handle" region peptide (pentapeptides 11P-15P)

Outcome

Inhibition of prorenin binding to receptors and prevention of end-organ damage (nephropathy and retinopathy)surrogate

Inhibition of non-proteolytic prorenin activation by a decoy peptide represents a potential novel therapeutic strategy for preventing end-organ damage in diabetes and hypertension.

Cite This Study

Mukarram Uddin (2007) studied this question.

synapsesocial.com/papers/6a70f1cd87f921057127fcb1 https://doi.org/10.2741/2716

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, "decoy peptide"

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, "decoy peptide"

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider